Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  GlycoMimetics, Inc.    GLYC

GLYCOMIMETICS, INC.

(GLYC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • The group usually releases earnings worse than estimated.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
GLYCOMIMETICS, INC.2.53%184
-
GILEAD SCIENCES, INC.8.70%79 386
VERTEX PHARMACEUTICALS-4.57%58 652
REGENERON PHARMACEUTICALS7.21%54 665
WUXI APPTEC CO., LTD.3.52%52 469
BEIGENE, LTD.33.52%31 458
GENMAB A/S9.09%28 585
BIONTECH SE24.62%24 461
HUALAN BIOLOGICAL ENGINEERI..16.79%13 889
ARGENX SE-4.38%13 245
MYOKARDIA, INC.208.58%11 993
-
MIRATI THERAPEUTICS, INC.-2.35%10 784
FATE THERAPEUTICS, INC.24.92%10 412
NEUROCRINE BIOSCIENCES, INC..14.02%10 061
ULTRAGENYX PHARMACEUTICAL I..-0.33%9 128
DENALI THERAPEUTICS INC.-12.81%8 758
More Results
Financials (USD)
Sales 2020 8,40 M - -
Net income 2020 -50,5 M - -
Net Debt 2020 - - -
P/E ratio 2020 -3,49x
Yield 2020 -
Capitalization 184 M 184 M -
Capi. / Sales 2020 21,9x
Capi. / Sales 2021 -
Nbr of Employees 57
Free-Float 97,8%
Upcoming event on GLYCOMIMETICS, INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating -
Growth (Revenue) -
Valuation -
Finances -
Profitability -
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes